When a patient is unfortunately found to have congenital heart disease, the next question to be faced is how to treat it. There are two main types of treatment options available: surgical and medical interventions. As simple as it sounds, there is either “surgical surgery” or “medical cardiac catheterization” or, of course, the more fashionable “medical-surgical mosaic (also known as hybridization) treatment”. For each specific patient, it is often the case that the cardiac surgeon recommends that the patient be “operated on” as soon as possible, while the cardiologist believes that the patient can be “catheterized” or that the patient can be followed up to see if it might heal on its own. In such cases, patients are often at a loss as to who to listen to. In fact, there are advantages and limitations to any treatment method. Surgery can be used for almost any “treatable congenital heart disease” and has a wide range of applications. Some so-called “minimally invasive” or “lateral incision” procedures are being questioned by insiders because of the potential for greater tissue damage in the body. In addition, the brain damage and neuropsychiatric dysfunction that may result from extracorporeal circulation is a problem that cannot be ignored. The biggest advantage of medical interventions is that they are “non-open”, requiring only peripheral vascular puncture, no extracorporeal circulation, no surgical scars, short hospitalization period, and now the price is close to or even lower than the cost of surgical procedures; however, they must be performed under X-ray fluoroscopy, and there is a certain radiation hazard (equivalent to one chest CT At the same time, interventional treatment of precardiac disease has its own very strict indications, and not any precardiac patient can undergo interventional treatment, and its scope of application is much narrower compared with that of surgical procedures. Mosaic (hybrid) therapy is an “appropriate” combination of medical and surgical procedures to treat some complex congenital heart diseases in order to improve the therapeutic effect and reduce complications. The indications are very strict, such as inlay treatment for left heart dysplasia (HLHS) and myoventricular septal defect (MVSD). Currently, many so-called “inlay” treatments in China have more or less problems. In a word, there is no perfect method, and the methods applied to different types of congenital heart disease, or even the same type of congenital heart disease, may be different. It should be judged according to the patient’s condition, the safety of the method and other specific circumstances, and the safest, effective and economical method for the patient should be chosen.